Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 13 drugs with upcoming expirations

Activity

Key Events

Jun 24, 2026TrialA Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications

Aug 30, 2024FDAPrevymis — PREVYMIS

Jun 26, 2024FDAOhtuvayre — OHTUVAYRE

Sep 16, 2022FDAEmend — APONVIE

Aug 13, 2021FDAWelireg — WELIREG

May 31, 2021FDANoxafil — NOXAFIL POWDERMIX KIT

Jan 19, 2021FDAVerquvo — VERQUVO

Aug 30, 2018FDAPifeltro — PIFELTRO

1 more events

Dec 19, 2017FDASteglatro — STEGLATRO

Details

Company Info

Regulatory

Regulatory Timeline

20111 event

FDADec 21

Isentress — ISENTRESS

Application NDA203045 (NDA)

20121 event

FDAFeb 7

Stromectol — SKLICE

Application NDA202736 (NDA)

20132 events

FDADec 20

Isentress — ISENTRESS

Application NDA205786 (NDA)

FDANov 25

Noxafil — NOXAFIL

Application NDA205053 (NDA)

20143 events

FDADec 19

Stromectol — SOOLANTRA

Application NDA206255 (NDA)

FDAAug 13

Belsomra — BELSOMRA

Application NDA204569 (NDA)

FDAMar 13

Noxafil — NOXAFIL

Application NDA205596 (NDA)

20152 events

FDADec 17

Emend — EMEND

Application NDA207865 (NDA)

FDADec 15

Bridion — BRIDION

Application NDA022225 (NDA)

20174 events

FDADec 19

Steglatro — STEGLATRO

Application NDA209803 (NDA)

FDANov 9

Emend — CINVANTI

Application NDA209296 (NDA)

FDANov 8

Prevymis — PREVYMIS

Application NDA209940 (NDA)

FDANov 8

Prevymis — PREVYMIS

Application NDA209939 (NDA)

20181 event

FDAAug 30

Pifeltro — PIFELTRO

Application NDA210806 (NDA)

20213 events

FDAAug 13

Welireg — WELIREG

Application NDA215383 (NDA)

FDAMay 31

Noxafil — NOXAFIL POWDERMIX KIT

Application NDA214770 (NDA)

FDAJan 19

Verquvo — VERQUVO

Application NDA214377 (NDA)

20221 event

FDASep 16

Emend — APONVIE

Application NDA216457 (NDA)

20242 events

FDAAug 30

Prevymis — PREVYMIS

Application NDA219104 (NDA)

FDAJun 26

Ohtuvayre — OHTUVAYRE

Application NDA217389 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)